PHATHOM PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Gain (Loss) on Extinguishment of Debt of -$829.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was -$829.00K.
- PHATHOM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$829.00K 10-Q · filed 2026-07-30 |
| 2026-03-31 | -$829.00K 10-Q · filed 2026-04-30 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |